DaVita Inc. (DVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
DVA POWR Grades
- DVA scores best on the Stability dimension, with a Stability rank ahead of 80.51% of US stocks.
- DVA's strongest trending metric is Stability; it's been moving up over the last 206 days.
- DVA's current lowest rank is in the Sentiment metric (where it is better than 37.7% of US stocks).
DVA Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for DVA is 9.24 -- better than 96.66% of US stocks.
- For DVA, its debt to operating expenses ratio is greater than that reported by 84.92% of US equities we're observing.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 11.16 for Davita Inc; that's greater than it is for 93.17% of US stocks.
- Stocks that are quantitatively similar to DVA, based on their financial statements, market capitalization, and price volatility, are FRTA, NCR, HBAN, CCB, and TPX.
- Visit DVA's SEC page to see the company's official filings. To visit the company's web site, go to www.davita.com.
DVA Price Target
For more insight on analysts targets of DVA, see our DVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $123.71 | Average Broker Recommendation | 1.94 (Hold) |
DVA Stock Price Chart Interactive Chart >
DVA Price/Volume Stats
| Current price | $125.41 | 52-week high | $129.59 |
| Prev. close | $125.94 | 52-week low | $75.30 |
| Day low | $125.15 | Volume | 302,400 |
| Day high | $126.46 | Avg. volume | 751,324 |
| 50-day MA | $112.56 | Dividend yield | N/A |
| 200-day MA | $103.23 | Market Cap | 13.32B |
DaVita Inc. (DVA) Company Bio
DaVita Healthcare Partners delivers dialysis services to patients with chronic kidney failure and end stage renal disease. The company was founded in 1994 and is based in Denver, Colorado.
DVA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $125.41 | $151.84 | 24% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Davita Inc. To summarize, we found that Davita Inc ranked in the 60th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 24.5% on a DCF basis. The most interesting components of our discounted cash flow analysis for Davita Inc ended up being:
- 54% of the company's capital comes from equity, which is greater than just 18.78% of stocks in our cash flow based forecasting set.
- Davita Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 1.8% of tickers in our DCF set.
- Relative to other stocks in its sector (Healthcare), Davita Inc has a reliance on debt greater than 86.92% of them.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 21% |
| 1% | 23% |
| 2% | 24% |
| 3% | 25% |
| 4% | 26% |
| 5% | 28% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DVA, try JAZZ, PRAH, VCEL, BDX, and MCK.
Latest DVA News From Around the Web
Below are the latest news stories about Davita Inc that investors may wish to consider to help them evaluate DVA as an investment opportunity.
Extraordinary Nurses at DaVita Kidney Care Honored with DAISY AwardsDaVita Kidney Care today announced that 60 of its nephrology nurses were honored with The DAISY Award for Extraordinary Nurses® during National Nurses Week. The award is part of the DAISY Foundation's mission to recognize the extraordinary, compassionate care that nurses provide to patients and families every day. |
Here's Why You Should Add DaVita (DVA) to Your Portfolio NowInvestor confidence is high on the DaVita (DVA) stock, courtesy of its solid prospects. |
5 of the Best Stocks to Buy Now for Striking Earnings GrowthHerbalife (HLF), DaVita (DVA), Apple (AAPL), Century Communities (CCS) & Repligen (RGEN) are the top stocks that flaunt attractive earnings growth at present. |
DaVita's (DVA) CEO Javier Rodriguez on Q1 2021 Results - Earnings Call TranscriptDaVita, Inc. (DVA) Q1 2021 Earnings Conference Call April 29, 2021 5:00 PM ET Company Participants Jim Gustafson – Vice President, Investor Relations Javier Rodriguez – Chief Executive Officer Joel Ackerman – Chief Financial Officer Conference Call Participants Pito Chickering – Deutsche Bank Kevin Fischbeck – Bank of America Justin... |
DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss MarkDaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1. |
DVA Price Returns
| 1-mo | 14.16% |
| 3-mo | 19.45% |
| 6-mo | 10.84% |
| 1-year | 58.25% |
| 3-year | 87.66% |
| 5-year | 62.72% |
| YTD | 6.82% |
| 2020 | 56.47% |
| 2019 | 45.80% |
| 2018 | -28.78% |
| 2017 | 12.54% |
| 2016 | -7.90% |
Continue Researching DVA
Want to do more research on Davita Inc's stock and its price? Try the links below:Davita Inc (DVA) Stock Price | Nasdaq
Davita Inc (DVA) Stock Quote, History and News - Yahoo Finance
Davita Inc (DVA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...